SSA
PRTK

Schonfeld Strategic Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13,900
Closed -$35.3K – 2651
2023
Q1 		$35.3K Sell
13,900
-8,000
-37% -$15.8K ﹤0.01% 1800
2022
Q4 		$41K Sell
21,900
-19,400
-47% -$48.4K ﹤0.01% 2274
2022
Q3 		$106K Buy
41,300
+25,200
+157% +$62.7K ﹤0.01% 2533
2022
Q2 		$31K Sell
16,100
-153,700
-91% -$335K ﹤0.01% 2272
2022
Q1 		$504K Buy
+169,800
New +$639K ﹤0.01% 1368
2018
Q4 		– Sell
-85,000
Closed -$825K – 1272
2018
Q3 		$825K Sell
85,000
-100
-0.1% -$1.01K 0.04% 469
2018
Q2 		$868K Buy
85,100
+10,100
+13% +$114K 0.05% 415
2018
Q1 		$975K Sell
75,000
-27,574
-27% -$411K 0.07% 324
2017
Q4 		$1.84M Sell
102,574
-21,314
-17% -$445K 0.15% 189
2017
Q3 		$3.11M Sell
123,888
-21,112
-15% -$491K 0.28% 113
2017
Q2 		$3.5M Buy
145,000
+75,017
+107% +$1.66M 0.36% 67
2017
Q1 		$1.35M Buy
+69,983
New +$1.1M 0.14% 217

Other funds holding PRTK

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Schonfeld Strategic Advisors's PRTK Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 13,900 shares — an estimated $35.3K sold.

Schonfeld Strategic Advisors first reported a position in PRTK in Q1 2017 and held it in 12 quarters. The position peaked at $3.5M in Q2 2017. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

  • Schonfeld Strategic Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 13,900 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $35.3K.
  • Schonfeld Strategic Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's Paratek Pharmaceuticals, Inc. position peaked at $3.5M in Q2 2017.
  • 66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.